Traditional use of the specie Maytenus macrocarpa (M. macrocarpa) is common among natives of the Amazon region in Peru. These populations describe therapeutic effects of M. macrocarpa against dysentery, hemorrhoids, rheumatism, arthritis, cleft nipples, sexual impotence, lumbago, bronchitis, diarrhea, flu and helminthic infections. 
INTRODUCTION

M. krukovii.
12 Moreover, Maytenus's species such as forsskaoliana and Blepharodes, have shown to produce neuro-toxic effects like sedation and decreased respiratory rate. 13 There are also experimental models to evaluate the anti-inflammatory activity, as carrageenan's plantar oedema test, 6, 14 and to evaluate the behavior of the rodent as Irwin test. [15] [16] [17] Additionally, the guidelines of the recent strategic plan of the World Health Organization, about traditional medicine indicate that nations must increase the scientific evidence 18 of medicinal plants. Overall the evidence is consistent with the anti-inflammatory role of M. macorcarpa, but also suggests the possibility of concomitant neurological side effects. This study aim focuses on exploring the anti-inflammatory and neurobehavioral activity of the ethanolic extract of the leaves of Maytenus macrocarpa in mice.
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SUBJECTS AND METHODS
Chemical and reagents
Plant material
Leaf from M. macrocarpa were collected in Madre de Dios (South-east, Peru). The plant was identified by Dra. Berta Loja Herrera (Centro de Investigación de Medicina Tradicional y Farmacología, FMH-USMP, Lima, 12, Perú). A voucher specimen was deposited at the Herbarium Vargas CUZ from the Universidad Nacional San Antonio Abad del Cuzco, numbers 3547 and 3653.
Ethanol extract preparation
The extract was prepared following the described methodology. 19 Briefly, first, the ground dried leaf of M. macrocarpa (Ruiz and Pav.) was macerated in ethanol 70% for a week. Second, macerated was filtered and placed in an evaporator. Third, a product obtained was dried in an oven for a period of 48 hours and stored in airtight containers in the refrigerator. Forth, the final product was dissolved in distilled water at concentrations which ensured a volume of oral administration that did not exceed 0.25 ml. 20 and the guide management and care of laboratory animals from the National Health Institute of Peru. 21 A couple of mice were isolated in cages, at a temperature of 22 ± 3°C, humidity between 40 to 70%, cycles light/darkness of 12 h, the average noise level lower than 70 dB, with free access to water and were provided with feed, in amounts of 5 g per mouse, 2 times daily.
In vivo experiments
The study was approved by the Research Institute of the School of Medicine at the Universidad de San Martin de Porres, following the principles and guidelines for animal research laboratory referred by the International Guiding Principles for Biomedical Research Involving Animals 20 and the Declaration on the use of animals in Biomedical Research. 22 
Irwin Test in mice
The test was conducted as an adaptation of the previously described. 17 The substance was administered to mice in a double-blind manner. Subsequently, the animals were observed during a one hour in time ranges of 15, 30, 45 and 60 min. The endpoints analyzed were the presence or absence of the following: lethality, convulsions, Straub tail, sedation, agitation, abnormal gait (rolling or toes), jumps, motor incoordination, piloerection, abdominal cramps, stereotypies (sniffing, chewing or head movements), head shaking, itching and abnormal breathing. Moreover, a training process was performed, regarding of the explored manifestations, by the use of the Pharmacology Lab Virtual Software 23 and Microlabs, 24 and by an in vivo pilot.
Carrageenin-induced paw edema in mice
This was performed as previously indicated.
14 The carrageenan 0.2% was injected subcutaneously into the mice plantar aponeurosis. The volume of the injected paw was measured before and after each injection with a LETICA digital plethysmometer (LE-750). Observations were made on 6 periods: pre-test (before the time of administration), 1, 2, 3, 4 and 5 hours after administration. The inhibitory activity was calculated using the formula: 25 Percent inhibition (%) = ((Ct − Co) control − (Ct − Co) treated) × 100 / (Ct − Co) control Ct = volume of the foot at the measurement point. Co = paw volume before carrageenan administration (pre-test)
Experimental groups
Ten experimental groups were included, each made up of 6 mice. 
RESULTS
M. macrocarpa effects on neurobehavioral
In general, the neurobehavioral presented by the effect of the leaf of M. macrocarpa were excitation, abnormal gait, abdominal cramps, piloerection and scratching. (See details in Table 1 ) Furthermore, statistical significance (Fisher test, p<0.05 and CI95%) were observed in specific doses when crossover with the control groups, so, It was observed excitation with leaf of M. macrocarpa at doses of 1250 and 1500 mg/kg, abnormal gait with M. macrocarpa at 750 mg/kg, abdominal cramps with M. macrocarpa at 1500 mg/kg, piloerection by M. macrocarpa at 750, 1250 and 1500 mg/kg and finally, scratching at 500, 1000 and 1500 mg/kg.
Anti-inflammatory activity of the leaf of M. macrocarpa
According to the paw edema, leaf of M. macrocarpa started their antiinflammatory activity at first hour at doses of 1000 and 1500 mg/kg and this is maintained through the 5 hours, in addition, in the second, third and four hours were showed an anti-inflammatory effect at a dose of 1250 mg/kg. (See details in Table 2) The method of the paw edema establish to analyze the third and fifth hour, because, in these checkpoints usually are presented the best efficacy, in this sense, in the third hour it was observed anti-inflammatory effect of the leaf of M. macrocarpa at doses of 1250 and 1500 mg/kg, but, in the fifth hour it was showed anti-inflammatory activity at doses of 1000, 1250 and 1500 mg/kg, inclusively, it was presented better effect than diclofenac at doses of M. macrocarpa of 1250 and 1500 mg/kg. (See details in Figure 1 ) Also, there was calculated the percentage of the inflammatory inhibition, so, It was shown inflammatory inhibition with all doses of the leaf of have demonstrated their anti-inflammatory effect in experimental rodent models. This study confirms the anti-inflammatory efficacy of the genus Maytenus and extends this to the leaves of Macrocarpa species. The anti-inflammatory activity of the macrocarpa species could be due to its secondary metabolites, in this regard, previous studies report the presence of flavonoids, phenols, diterpenes, triterpenes and sesquiterpene and spermidinics alkaloids, among others. 3, 13, [26] [27] [28] [29] Subsequent studies are required to prove the possible anti-inflammatory effects of these molecules. Contrasting the anti-inflammatory effectiveness of the genus Maytenus, model studies in carrageenan plantar edema, show a percent inhibition of swelling of 95% for M. rigida at doses of 750 mg/kg, 30 55.9% for M. dark at 200 mg/kg, 26 M. heterophylla 51% at 120 mg/kg and 35% for M. senegalensis at 120 mg/kg, 6 in contrast, this study shows maximum inhibition of 74.14% at 1200 mg/kg; these findings show variability in this pharmacological property, which could be due to the different origin of the species, the source region, the part of the plant used or the presence of a specific secondary metabolite. As the carrageenan experimental model is initiated by tissue injury and activation of the arachidonic acid cascade, 31 our findings suggest a peripheral mechanism for the action of the ethanolic extract from the leaves of M. macrocarpa. In this study, it was observed that M. macrocarpa, induced behavioral effects in the rodent, which could be explained by blood-brain barrier cross-over of the metabolites. [32] [33] The neuro behavioral expressions by the action of the M. macrocarpa put on a state of alert the use of the plant as a natural anti-inflammatory medicine and present phenotypic characteristics of conventional drugs, where most, presents side effects are considered therapeutic. In this regard, between the neurological manifestations observed, we can highlight the abnormal gait, which expresses an impairment of motor coordination system of the brain, typical of drugs such as anesthetics, benzodiazepines, alcohol, among others; 34 this is why, despite having confirmed an anti-inflammatory pharmacological property of M. macrocarpa, with an important traditional root and scientific support, is advisable to alert the community, that they should consider common precautions of the drug, for the use of this medicinal plant.
CONCLUSION
The study probes the anti-inflammatory effect of the leaf of M. macrocarpa and concomitant neurobehavioral activity. Also, the therapeutic anti-inflammatory effect was observed in a range of doses at 1000 to 1500 mg/kg.
GRAPHICAL ABSTRACT
• Maytenus macrocarpa leaves presented anti-inflammatory activity • Maytenus macrocarpa leaves presented concomitants neurobehavioral side effects • There is a need for further research in order to discover new effects and determine the safety of the plants. 
